n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide in 32 studies

Compound Research Comparison

Studies (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)	Trials (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)	Recent Studies (post-2010) (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)	Studies (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide)	Trials (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide)	Recent Studies (post-2010) (2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide)
214	5	58	158	2	52

Protein Interaction Comparison

Protein	Taxonomy	n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50)	2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide (IC50)
Adenosine receptor A3	Homo sapiens (human)		0.0017

Research

Studies (32)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (15.63)	18.2507
2000's	16 (50.00)	29.6817
2010's	9 (28.13)	24.3611
2020's	2 (6.25)	2.80

Authors

Authors	Studies
Jacobson, KA; Ji, XD; Kim, HO; Olah, ME; Siddiqi, SM; Stiles, GL	1
Jacobson, KA; Ji, XD; Li, AH; Melman, N; Moro, S	1
Barak, D; Biadatti, T; Chen, W; Gao, ZG; Jacobson, KA; Johnson, CR; Kim, SG; Kim, SK; Lee, K	1
Chenard, LK; DeNinno, MP; DiRico, KJ; Eller, C; Etienne, JB; Hill, RJ; Kennedy, SP; Knight, DR; Kong, J; Masamune, H; Oleynek, JJ; Tickner, JE; Tracey, WR	1
Chun, MW; Gao, ZG; Gunaga, P; Jacobson, KA; Jeong, LS; Jin, DZ; Kim, HO; Kim, YC; Melman, N; Moon, HR; Shin, DH	1
Elzein, E; Maa, T; Palle, V; Wu, Y; Zablocki, J; Zeng, D	1
Chun, MW; Gao, ZG; Jacobson, KA; Jeong, LS; Kim, HO; Kim, MJ; Kim, SK	1
Baraldi, PG; Borea, PA; Bovero, A; Fruttarolo, F; Moorman, A; Pineda de Las Infantas, MJ; Preti, D; Romagnoli, R; Tabrizi, MA; Varani, K	1
Cappellacci, L; Costa, B; Franchetti, P; Grifantini, M; Klotz, KN; Lavecchia, A; Martini, C; Novellino, E; Pasqualini, M; Petrelli, R; Vita, P	1
Duong, HT; Gao, ZG; Jacobson, KA; Joshi, BV; Kim, SK; Tchilibon, S	1
Frazier, CR; Linden, J; Macdonald, TL; Zhu, R	1
Gao, ZG; Jacobson, KA	1
Auchampach, JA; Gao, ZG; Gizewski, E; Jacobson, KA; Kumar, D; Melman, A; Wan, TC	1
Choe, SA; Choi, WJ; Gao, ZG; Hou, X; Jacobson, KA; Jeong, LS; Kim, HO; Klutz, AM; Lee, HW; Lee, SK; Moon, HR; Pal, S; Tosh, DK	1
Chinn, M; Choi, WJ; Gao, ZG; Jacobson, KA; Jeong, LS; Jung, YH; Kim, HO; Lee, HW; Moon, HR; Patel, A	1
Baraldi, PG; Borea, PA; Preti, D; Varani, K	1
Federico, S; Jacobson, KA; Jayasekara, PS; Kozma, E; Moro, S; Paoletta, S; Spalluto, G; Squarcialupi, L	1
Gao, ZG; Jacobson, KA; Moss, SM; Paoletta, S; Toti, KS; Van Calenbergh, S	1
Auchampach, JA; Finley, A; Gao, ZG; Gizewski, ET; Jacobson, KA; Moss, SM; Paoletta, S; Salvemini, D; Tosh, DK	1
Amin, EA; Dosa, PI	1
Ahn, S; Cheong, JH; Jacobson, KA; Jeong, LS; Jin, SH; Kim, G; Kim, HJ; Kim, J; Lee, E; Lee, M; Noh, M; Yu, J	1
Federico, S; Kachler, S; Klotz, KN; Margiotta, E; Moro, S; Pastorin, G; Salmaso, V; Spalluto, G	1
Ahn, S; An, S; Choi, H; Jeong, LS; Ko, H; Noh, M; Pyo, JJ; Shin, JC; Yu, J	1
Campbell, RG; Chen, E; Gao, ZG; Jacobson, KA; Liston, TE; Poe, RB; Salmaso, V; Suresh, RR	1
Abbracchio, MP; Jacobson, KA; Jiang, JL; Kim, YC; Sei, Y; Yao, Y	1
Jacobson, KA; Jiang, JL; Liang, BT; Stambaugh, K	1
Jahania, MS; Kraft, KR; Lasley, RD; Mentzer, RM; Narayan, P; Partin, EL	1
Day, YJ; Gao, Z; Li, BS; Linden, J	1
Bober, L; Caux, C; de Bouteiller, O; Deno, G; Du, XK; Fan, X; Fossetta, J; Jackson, J; Lundell, D; Lunn, C; Palmer, RK; Soudé-Bermejo, A	1
Bai, GY; Kim, SH; Kim, SZ; Park, WH; Yuan, K	1
Dolezel, P; Frydrych, I; Mlejnek, P	1
Ambrósio, AF; Cordeiro, MF; Elvas, F; Galvao, J; Martins, T; Santiago, AR	1

Reviews

4 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

Article	Year
Adenosine receptors as therapeutic targets. Nature reviews. Drug discovery, 2006, Volume: 5, Issue:3 Topics: Animals; Disease; Drug Therapy; Humans; Ligands; Molecular Structure; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Signal Transduction; Structure-Activity Relationship	2006
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications. Journal of medicinal chemistry, 2012, Jun-28, Volume: 55, Issue:12 Topics: Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Chemistry, Pharmaceutical; Disease; Humans; Ligands; Receptor, Adenosine A3	2012
Fluorescent ligands for adenosine receptors. Bioorganic & medicinal chemistry letters, 2013, Jan-01, Volume: 23, Issue:1 Topics: Boron Compounds; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Ligands; Protein Binding; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1	2013
Tactical Approaches to Interconverting GPCR Agonists and Antagonists. Journal of medicinal chemistry, 2016, Feb-11, Volume: 59, Issue:3 Topics: Animals; Humans; Ligands; Models, Molecular; Molecular Structure; Receptors, G-Protein-Coupled; Structure-Activity Relationship	2016

Other Studies

28 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide

Article	Year
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. Journal of medicinal chemistry, 1994, Oct-14, Volume: 37, Issue:21 Topics: Adenosine; Adenylyl Cyclase Inhibitors; Animals; Brain; Cell Membrane; CHO Cells; Cricetinae; Molecular Structure; Rats; Receptors, Purinergic P1; Recombinant Proteins; Structure-Activity Relationship	1994
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. Journal of medicinal chemistry, 1998, Aug-13, Volume: 41, Issue:17 Topics: Adenosine; Animals; Binding, Competitive; Brain; Dihydropyridines; Drug Design; Humans; Iodine Radioisotopes; Kinetics; Models, Molecular; Molecular Conformation; Molecular Structure; Purinergic P1 Receptor Antagonists; Pyridines; Radioligand Assay; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A3; Recombinant Proteins; Structure-Activity Relationship	1998
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. Journal of medicinal chemistry, 2002, Sep-26, Volume: 45, Issue:20 Topics: Adenosine; Animals; Binding, Competitive; CHO Cells; Cricetinae; Epoxy Compounds; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Models, Molecular; Mutation; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Radioligand Assay; Rats; Receptor, Adenosine A3; Receptors, Purinergic P1; Ribose; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship	2002
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor. Journal of medicinal chemistry, 2003, Jan-30, Volume: 46, Issue:3 Topics: Adenosine; Amides; Cell Line; Humans; Isoxazoles; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Structure-Activity Relationship	2003
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. Journal of medicinal chemistry, 2003, Aug-28, Volume: 46, Issue:18 Topics: Adenosine; Animals; Cerebral Cortex; CHO Cells; Corpus Striatum; Cricetinae; Humans; Ligands; Purinergic P1 Receptor Agonists; Radioligand Assay; Rats; Receptor, Adenosine A3; Structure-Activity Relationship; Thionucleosides	2003
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists. Journal of medicinal chemistry, 2004, Sep-09, Volume: 47, Issue:19 Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Cricetinae; Humans; Molecular Structure; Receptor, Adenosine A3; Structure-Activity Relationship	2004
Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor. Bioorganic & medicinal chemistry letters, 2004, Oct-04, Volume: 14, Issue:19 Topics: Adenosine; Adenosine A3 Receptor Agonists; Binding Sites; Drug Design; Hydrogen Bonding; Receptor, Adenosine A3; Structure-Activity Relationship	2004
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists. Journal of medicinal chemistry, 2004, Oct-21, Volume: 47, Issue:22 Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Adenosine A3 Receptor Agonists; Amides; Animals; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; Ligands; Radioligand Assay; Structure-Activity Relationship; Sulfonamides; Uronic Acids	2004
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. Journal of medicinal chemistry, 2005, Mar-10, Volume: 48, Issue:5 Topics: Adenosine; Adenylyl Cyclase Inhibitors; Animals; Binding, Competitive; Brain; Cattle; CHO Cells; Cricetinae; Cricetulus; Humans; In Vitro Techniques; Models, Molecular; Purinergic P1 Receptor Agonists; Radioligand Assay; Rats; Receptors, Purinergic P1; Ribose	2005
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6 Topics: Adenine; Adenosine A3 Receptor Agonists; Animals; Binding Sites; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Humans; Models, Molecular; Nucleosides; Radioligand Assay; Rats; Receptor, Adenosine A3; Stereoisomerism; Structure-Activity Relationship	2005
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists. Bioorganic & medicinal chemistry letters, 2006, May-01, Volume: 16, Issue:9 Topics: Adenosine A3 Receptor Agonists; Adenosine-5'-(N-ethylcarboxamide); Cell Line; Humans; Molecular Structure; Structure-Activity Relationship	2006
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9 Topics: Adenosine; Adenosine A3 Receptor Agonists; Alkanes; Animals; Binding Sites; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Models, Chemical; Nucleosides; Ribose; Structure-Activity Relationship	2008
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists. Journal of medicinal chemistry, 2008, Oct-23, Volume: 51, Issue:20 Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Humans; Molecular Structure; Rats; Receptor, Adenosine A3; Structure-Activity Relationship; Thionucleosides	2008
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists. Bioorganic & medicinal chemistry, 2009, Dec-01, Volume: 17, Issue:23 Topics: Adenosine A3 Receptor Agonists; Amides; Animals; CHO Cells; Cricetinae; Cricetulus; Humans; Kinetics; Magnetic Resonance Spectroscopy; Radioligand Assay; Spectrometry, Mass, Fast Atom Bombardment; Thionucleosides	2009
Synthesis and evaluation of N⁶-substituted apioadenosines as potential adenosine A₃ receptor modulators. Bioorganic & medicinal chemistry, 2014, Aug-01, Volume: 22, Issue:15 Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Binding Sites; CHO Cells; Cricetinae; Cricetulus; HEK293 Cells; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Receptor, Adenosine A1; Receptor, Adenosine A3; Receptors, Adenosine A2; Structure-Activity Relationship	2014
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. Journal of medicinal chemistry, 2014, Dec-11, Volume: 57, Issue:23 Topics: Adenosine A3 Receptor Agonists; Animals; CHO Cells; Cricetulus; Humans; Mice; Neuralgia; Structure-Activity Relationship	2014
Polypharmacology of N Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17 Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; Cell Line; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Mice; Mice, Inbred C57BL; Polypharmacology; PPAR delta; PPAR gamma; Receptor, Adenosine A3	2017
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A European journal of medicinal chemistry, 2018, Sep-05, Volume: 157 Topics: Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Purinergic P1 Receptor Antagonists; Pyrimidines; Receptor, Adenosine A3; Structure-Activity Relationship; Triazoles	2018
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ. Bioorganic & medicinal chemistry, 2020, 01-01, Volume: 28, Issue:1 Topics: Adenosine; Adiponectin; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mesenchymal Stem Cells; Molecular Docking Simulation; Molecular Structure; PPAR delta; Selenium; Structure-Activity Relationship	2020
Selective A ACS medicinal chemistry letters, 2022, Apr-14, Volume: 13, Issue:4 Topics:	2022
Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochemical and biophysical research communications, 1997, Mar-17, Volume: 232, Issue:2 Topics: Adenosine; Apoptosis; Dihydropyridines; DNA Fragmentation; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrazoles; Quinazolines; Triazoles	1997
A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. The American journal of physiology, 1997, Volume: 273, Issue:1 Pt 2 Topics: Adenosine; Animals; Cardiotonic Agents; Cell Hypoxia; Cells, Cultured; Chick Embryo; Dihydropyridines; Heart; Heart Ventricles; Myocardial Ischemia; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Xanthines	1997
Species-dependent hemodynamic effects of adenosine A3-receptor agonists IB-MECA and Cl-IB-MECA. The American journal of physiology, 1999, Volume: 276, Issue:6 Topics: Adenosine; Animals; Coronary Circulation; Coronary Vessels; Dihydropyridines; Female; Hemodynamics; In Vitro Techniques; Male; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrimidines; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Swine; Triazoles; Vasodilation	1999
A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Molecular pharmacology, 2001, Volume: 59, Issue:1 Topics: Adenosine; Animals; Apoptosis; Leukemia, Basophilic, Acute; Mast Cells; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Radioligand Assay; Rats; Receptor, Adenosine A3; Receptors, Purinergic P1; Signal Transduction; Tumor Cells, Cultured; Ultraviolet Rays	2001
Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Molecular pharmacology, 2003, Volume: 63, Issue:2 Topics: Adenosine; Binding Sites; Calcium; Cell Membrane; Cells, Cultured; Dendritic Cells; Humans; Iodine Radioisotopes; Monocytes; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1	2003
Stimulation of ANP secretion by 2-Cl-IB-MECA through A(3) receptor and CaMKII. Peptides, 2008, Volume: 29, Issue:12 Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Atrial Natriuretic Factor; Calcium; Calcium Channels, L-Type; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP; Extracellular Fluid; Heart Atria; In Vitro Techniques; Inositol 1,4,5-Trisphosphate Receptors; Male; Myocardial Contraction; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A3; Ryanodine Receptor Calcium Release Channel; Type C Phospholipases	2008
Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. Journal of physiology and biochemistry, 2013, Volume: 69, Issue:3 Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; CHO Cells; Cricetulus; Cytotoxins; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-akt; Receptor, Adenosine A3; Signal Transduction; Transfection	2013
Adenosine A3 receptor activation is neuroprotective against retinal neurodegeneration. Experimental eye research, 2015, Volume: 140 Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Animals, Newborn; Apoptosis; Cell Survival; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluorescent Antibody Technique, Indirect; In Situ Nick-End Labeling; Intravitreal Injections; Male; N-Methylaspartate; Neuroprotection; Optic Nerve Injuries; Organ Culture Techniques; Rats; Rats, Wistar; Receptor, Adenosine A3; Retina; Retinal Degeneration; Retinal Neurons	2015